Literature DB >> 26664128

Medical devices for restless legs syndrome - clinical utility of the Relaxis pad.

Ulrike H Mitchell1.   

Abstract

Restless Legs Syndrome or Willis-Ekbom Disease, a neurosensory disorder, can be treated with pharmaceuticals or conservatively. This review focuses on conservative treatments, more specifically on treatments with medical devices. Two modes of action, enhancement of circulation and counter stimulation, are introduced. Medical devices that use enhancement of circulation as their mechanism of action are whole body vibration, pneumatic compression, and near-infrared light. Medical devices that use counter stimulation include transcutaneous electrical nerve stimulation and the vibration Relaxis pad. The clinical utility of the Relaxis pad and its place in therapy is proposed.

Entities:  

Keywords:  RLS/WED; conservative treatment; near-infrared light; pneumatic compression; whole body vibration

Year:  2015        PMID: 26664128      PMCID: PMC4671777          DOI: 10.2147/TCRM.S87208

Source DB:  PubMed          Journal:  Ther Clin Risk Manag        ISSN: 1176-6336            Impact factor:   2.423


  42 in total

1.  Measurement of the penetration depths of red and near infrared light in human "ex vivo" tissues.

Authors:  S Stolik; J A Delgado; A Pérez; L Anasagasti
Journal:  J Photochem Photobiol B       Date:  2000-09       Impact factor: 6.252

2.  Whole-body vibration exercise leads to alterations in muscle blood volume.

Authors:  K Kerschan-Schindl; S Grampp; C Henk; H Resch; E Preisinger; V Fialka-Moser; H Imhof
Journal:  Clin Physiol       Date:  2001-05

3.  Restless legs syndrome.

Authors:  K A EKBOM
Journal:  Neurology       Date:  1960-09       Impact factor: 9.910

4.  Nitric oxide-mediated arteriolar dilation after endothelial deformation.

Authors:  D Sun; A Huang; F A Recchia; Y Cui; E J Messina; A Koller; G Kaley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-02       Impact factor: 4.733

5.  Nitric oxide is released into circulation with whole-body, periodic acceleration.

Authors:  Marvin A Sackner; Emerance Gummels; Jose A Adams
Journal:  Chest       Date:  2005-01       Impact factor: 9.410

Review 6.  Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.

Authors:  Richard P Allen; Daniel Picchietti; Wayne A Hening; Claudia Trenkwalder; Arthur S Walters; Jacques Montplaisi
Journal:  Sleep Med       Date:  2003-03       Impact factor: 3.492

7.  Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome.

Authors:  Arthur S Walters; Cheryl LeBrocq; Anjana Dhar; Wayne Hening; Ray Rosen; Richard P Allen; Claudia Trenkwalder
Journal:  Sleep Med       Date:  2003-03       Impact factor: 3.492

8.  Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS.

Authors:  Clete A Kushida; Richard P Allen; Mark J Atkinson
Journal:  Sleep Med       Date:  2004-09       Impact factor: 3.492

9.  Sex and the risk of restless legs syndrome in the general population.

Authors:  Klaus Berger; Jan Luedemann; Claudia Trenkwalder; Ulrich John; Christof Kessler
Journal:  Arch Intern Med       Date:  2004-01-26

10.  Restless legs syndrome: an historical note.

Authors:  Giorgio Coccagna; Roberto Vetrugno; Carolina Lombardi; Federica Provini
Journal:  Sleep Med       Date:  2004-05       Impact factor: 3.492

View more
  2 in total

1.  Decreased Symptoms without Augmented Skin Blood Flow in Subjects with RLS/WED after Vibration Treatment.

Authors:  Ulrike H Mitchell; Sterling C Hilton; Erik Hunsaker; Jan Ulfberg
Journal:  J Clin Sleep Med       Date:  2016-07-15       Impact factor: 4.062

Review 2.  Restless Legs Syndrome: Contemporary Diagnosis and Treatment.

Authors:  Thomas R Gossard; Lynn Marie Trotti; Aleksandar Videnovic; Erik K St Louis
Journal:  Neurotherapeutics       Date:  2021-04-20       Impact factor: 7.620

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.